Welcome to our dedicated page for PLIANT THERAPEUTICS SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pliant Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing integrin-based therapeutics. Recent 8-K reports cover quarterly financial results, corporate updates for the PLN-101095 oncology program, material agreements, at-the-market equity offering arrangements, and amendments to the company’s stockholder rights agreement and Series A Junior Participating Preferred Purchase Rights.
Proxy and governance filings describe board composition, director retirements, committee roles, executive compensation, equity awards, and stockholder voting matters. Other material-event reports record officer appointments or departures and changes affecting security-holder rights, connecting the company’s capital structure and governance disclosures to its clinical-stage operating model.
ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger, report beneficial ownership of Pliant Therapeutics, Inc. common stock. Private investment funds managed by ADAR1 Capital Management hold 5,509,724 shares of common stock, representing 8.9% of the class based on 61,920,154 shares outstanding as of June 30, 2026.
Both ADAR1 Capital Management and Mr. Schneeberger report shared voting and dispositive power over 5,509,724 shares and no sole voting or dispositive power. Mr. Schneeberger files as a control person with respect to shares beneficially owned by ADAR1 Capital Management, which is identified as an investment adviser. The filing includes a joint filing agreement between the reporting persons.
Pliant Therapeutics, Inc. received an amended Schedule 13G/A filing in which several Citadel-affiliated entities and Kenneth Griffin reported their beneficial ownership of the company’s common stock. Based on 61,920,249 Shares outstanding as of May 8, 2026, the group reports holdings below 5% of the class.
Kenneth Griffin may be deemed to beneficially own 2,143,426 Shares, representing 3.5% of the outstanding common stock, through various Citadel entities. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,418,022 Shares (2.3%), Citadel Securities LLC 673,114 Shares (1.1%), and each of Citadel Securities Group LP and Citadel Securities GP LLC 725,404 Shares (1.2%), all with shared, not sole, voting and dispositive power.
Pliant Therapeutics, Inc. reported second quarter 2026 results and provided a corporate update centered on its oncology and drug-delivery platforms. Lead asset PLN-101095, an oral dual-selective inhibitor of αvβ8 and αvβ1 integrins, is being evaluated in FORTIFY, a Phase 1a/1b trial in immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.
The company highlighted that FORTIFY enrollment across three indication-expansion cohorts remains strong and ahead of schedule, with up to 102 patients planned and interim data expected in 2027. Updated Phase 1 monotherapy biomarker data showed coordinated T‑cell reactivation signals in responders, including increases in IFN‑γ, CXCL9 and granzyme‑B, suggesting a shift in the tumor microenvironment that may potentially resensitize tumors to pembrolizumab.
Pliant is advancing an integrin-targeted delivery platform for tissue-specific delivery of drug payloads, including siRNAs, and plans additional details, including initial treatment indications, in the second half of 2026. For the quarter, research and development expenses were $16.7 million and general and administrative expenses were $7.1 million, contributing to a net loss of $22.4 million, all substantially lower than the prior-year period. Cash, cash equivalents and short-term investments totaled $159.6 million as of June 30, 2026, which the company expects to fund operations into the second half of 2028.
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, now primarily focused on its oral solid-tumor candidate PLN-101095 and an integrin-targeted delivery platform. Development of bexotegrast in idiopathic pulmonary fibrosis was discontinued in 2025 after an unfavorable risk‑benefit profile and related restructuring.
For the quarter ended June 30, 2026, Pliant reported a net loss of $22.4 million, about half the $43.3 million loss a year earlier, driven by lower research and development and general and administrative expenses following the 2025 restructuring and program reprioritization. Research and development expense was $16.7 million versus $32.2 million, and general and administrative expense was $7.1 million versus $13.4 million.
As of June 30, 2026, Pliant held $159.6 million in cash, cash equivalents, restricted cash and short-term investments and had no long‑term debt, but an accumulated deficit of $901.8 million. Management believes existing capital will fund operations for at least 12 months and beyond. An at‑the‑market facility allows issuance of up to $50.0 million of common stock, with no sales to date.
Pliant Therapeutics, Inc. director Robert Iannone filed an initial statement of beneficial ownership on Form 3. The structured data shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, or other transactions in this filing.
PLIANT THERAPEUTICS, INC. director Robert Iannone received a grant of 60,000 stock options on July 9, 2026. The options have an exercise price of $1.13 per share and are exercisable for common stock until July 9, 2036. According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of July 9, 2026, conditioned on Iannone’s continuous service to the company.
Pliant Therapeutics, Inc. director Borellini Flavia has filed an initial statement of beneficial ownership as a reporting person. The filing lists her status as a director of the company and reports no equity transactions or derivative positions, providing an initial disclosure of her insider status without detailing current holdings.
PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026. The option has an exercise price of $1.13 per share and expires on July 9, 2036. Vesting occurs as 1/36th of the option each month starting on July 9, 2026, subject to her continued service, and all 60,000 option shares are reported as held directly after the award.
Pliant Therapeutics, Inc. expanded its Board of Directors from seven to nine members effective July 9, 2026, and appointed Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director to fill the new seats. Both have been determined to be independent directors under SEC and Nasdaq rules. Dr. Iannone joins the Research and Development Committee, while Dr. Borellini becomes its chairperson. Each new director will receive an annual cash retainer of $40,000, pro-rated for partial service periods; Dr. Iannone will receive an additional $7,500 for R&D Committee membership and Dr. Borellini $15,000 for serving as R&D Committee chair. On the effective date, each was granted an option to purchase 60,000 shares of common stock, vesting in substantially equal monthly installments over three years, subject to continued Board service. The company also entered into its standard indemnification agreements with both directors.
Pliant Therapeutics director Gayle A. Crowell received a compensation grant of stock options. The award covers 70,000 options to buy Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.
According to the vesting schedule, 25% of the options vest on October 1, 2026, another 25% on January 1, 2027, and another 25% on April 1, 2027. The remaining 25% vest on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, subject to Crowell’s continued service as a director.